在阿尔茨海默氏症中研究互白素-8:综合性审查
Delia Righi1, Carlo Manco1, Matteo Pardini2
1Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Journal of Alzheimer's disease : JAD
|November 19, 2024
概括
介质素-8 (IL-8) 在阿尔茨海默氏症 (AD) 神经退行症中起着复杂的作用,影响炎症和脑细胞损伤. 需要进一步的研究才能充分理解IL-8在AD病理学的多方面的参与.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 的发展与神经炎症有关.
- 中枢神经系统的炎症与神经退行相关.
- 互白素-8 (IL-8) 在神经退行症中的确切作用尚不清楚.
研究的目的:
- 审查关于IL-8参与阿尔茨海默病的现有证据.
- 阐明在AD病理学中IL-8的结构,功能和调节.
主要方法:
- 对IL-8和AD研究的文献综述.
- 分析IL-8作为细胞因子的已知功能.
- 检查IL-8在大脑中的存在和释放.
主要成果:
- IL-8是一种促炎性细胞因子.
- IL-8吸引了血液中的中性粒细胞.
- 在大脑中,微质细胞释放IL-8作为对炎症信号的反应.
结论:
- 在AD中IL-8的作用是复杂的,涉及神经炎症,神经毒性,血脑屏障破坏和氧化应激.
- 了解IL-8机制对于AD研究至关重要.
- 在AD中需要进一步描述IL-8的特征.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.7K
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165